Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus.

Hyperuricemia, frequently observed following kidney transplantation, may adversely affect graft survival. Although hyperuricemia is a well-known adverse effect of cyclosporine (CsA), a similar effect of tacrolimus (Tac) remains debatable. Hyperuricemia is also seen after oral fructose intake in beverages and processed foods. This sugar is blamed for the epidemic of obesity and metabolic syndrome. The aim of our study was to compare the effects of CsA and Tac on an acute oral fructose load in terms of plasma uric acid, serum lipids, and blood pressure in kidney transplant patients. Thirty-two kidney transplant recipients treated with CsA- or Tac-based triple (calcineurin inhibitor + mycophenolate mofetil + prednisone) immunosuppressive therapy displaying stable allograft function (mean glomerular filtration rate = 53 mL/min/1.73m(2)) received an oral challenge with 70 g of fructose. Serum uric acid, lipids, and blood pressure were measured before as well as 60, 120, 180, and 240 minutes after fructose administration. A significant increase in serum uric acid was observed in both groups after oral fructose administration (P < .001). A peak increase in serum uric acid was recorded at 120 minutes after fructose intake. Serum total, LDL, and HDL cholesterol also significantly decreased and serum triglycerides increased to a similar extent in both CsA and Tac groups. No significant changes in blood pressure were observed after fructose consumption. Oral fructose intake induced an acute rise in serum uric acid and triglycerides and decrease in serum cholesterol among kidney transplant recipients. Those changes were similar among patients treated with CsA or Tac.

[Local treatment with tumor necrosis factor alpha in a patient with lung cancer]. / Miejscowe leczenie czynnikiem martwicy nowotworów-alpha u chorej z guzem pluca.

Tumor Necrosis Factor alfa (TNFa) is a cytokine with cytolytic and cytotoxic properties. First clinical trials in which TNF was administered parenterally date back to early 70-ties. Soon it was noticed that when administered strictly to the tumor mass TNF exhibits high anti-tumor efficacy, exemplified by total or at least substantial regression of the tumor mass while producing minor and controllable symptoms. In this paper the case of local administration of the recombinant TNFa directly into the tumor mass constricting the bronchus was presented.

[Non-Hodgkin's lymphoma: diagnostic problems]. / Chloniak z limfocytów t obwodowych--problemy diagnostyczne.

The aim of this article was to describe rarely occurred non-Hodgkin's lymphomas from peripheral lymphocyte T. Epidemiology, course of the disease and difficulties of diagnostic was described with the special regards of early diagnostic.

[Clinical evaluation of disodium cromoglycate with beta-2-agonist in therapy of patients with atopic bronchial asthma (preliminary study)]. / Ocena przydatnosci klinicznej kromoglikanu dwusodowego w polaczeniu z beta-2-agonista w leczeniu chorych na atopowa astme oskrzelowa (badania wstepne).

In 38 patients with atopic bronchial asthma DNCG (disodium cromoglycate) and DNCG comp. (disodium cromoglycate and reproterol hydrochloride) were applied in inhalation way. After 7 days course spirometric values were monitoring in all patients. Decrease of Raw values and increases of FEF50 and FEV1 were noticed in all patients, especially in asthmatics treated with DNCG comp. Obtained results suggest a good clinical effect and improvement of spirometric values in patients with atopic bronchial asthma during DNCG and DNCG comp. therapy.

[Alpha fetoprotein levels in the serum and bronchoalveolar lavage fluid in patients with lung cancer and other diseases of the respiratory system]. / Stezenie alfa-fetoproteiny w surowicy i materiale z plukania oskrzelowo-pecherzykowego chorych na raka pluca i inne choroby ukladu oddechowego.

Concentration of alpha-fetoprotein (AFP) may be increased in some type of lung cancer. In the study concentration of AFP was evaluated in serum and broncho-alveolar lavage fluid (BALF) in patients with lung cancer. The values of concentration were compared with results obtained from patients with other diseases of the respiratory tract. Examinations were performed in 14 patients with lung cancer, 12 with sarcoidosis, 23 with chronic obstructive bronchitis and 16 with acute bronchitis. Liver pathology was excluded according to biochemical analytical tests. In all patients bronchofibroscopy was performed and BALF was obtained in routine way. Concentration of AFP in serum and BALF was determined by immuno-assay technique. In performed examinations non significant increase of AFP concentration was determined in serum and BALF of patients with lung cancer. However, obtained values were increased twice than in patients with acute bronchitis. Moreover, it was noticed that in patients with chronic obstructive bronchitis the AFP concentration was the highest, especially in the group treated by steroids. The study indicates that evaluation of AFP concentration is out of value in diagnosis and differentiation of lung cancer. It seems to be necessary to continue the examinations for explanation a role of steroids in inflammatory process and increase of AFP concentration.